| Item Type | Name |
|
Academic Article
|
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features.
|
|
Academic Article
|
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
|
|
Academic Article
|
Clinical genomics of renal epithelial tumors.
|
|
Academic Article
|
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
|
|
Academic Article
|
Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.
|
|
Academic Article
|
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
|
|
Academic Article
|
Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
|
|
Concept
|
Kidney Failure, Chronic
|
|
Concept
|
Kidney
|
|
Concept
|
Kidney Neoplasms
|
|
Concept
|
Kidney Pelvis
|
|
Concept
|
Kidney Function Tests
|
|
Academic Article
|
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
|
|
Academic Article
|
The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
|
|
Academic Article
|
Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome--clinicopathological features and comparative genomic analysis of 3 cases.
|
|
Academic Article
|
Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.
|
|
Academic Article
|
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
|
|
Academic Article
|
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
|
|
Academic Article
|
Adjuvant and neoadjuvant therapy in renal cell carcinoma.
|
|
Academic Article
|
Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.
|
|
Academic Article
|
Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures.
|
|
Academic Article
|
Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma.
|
|
Academic Article
|
Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease.
|
|
Academic Article
|
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.
|
|
Academic Article
|
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
|
|
Academic Article
|
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
|
|
Academic Article
|
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
|
|
Academic Article
|
Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study.
|
|
Academic Article
|
Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.
|
|
Academic Article
|
Kidney cancer. Clinical practice guidelines in oncology.
|
|
Academic Article
|
Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience.
|
|
Academic Article
|
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.
|
|
Academic Article
|
Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis.
|
|
Academic Article
|
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
|
|
Academic Article
|
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Targeted therapy for locally advanced renal cell carcinoma.
|
|
Academic Article
|
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
|
|
Academic Article
|
Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
|
|
Academic Article
|
Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Long-term management of patients with metastatic renal cell carcinoma on targeted agents.
|
|
Academic Article
|
Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.
|
|
Academic Article
|
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.
|
|
Academic Article
|
Emerging targeted therapies in metastatic renal cell carcinoma.
|
|
Academic Article
|
Adjuvant and neoadjuvant therapy in renal cell carcinoma.
|
|
Academic Article
|
Ten years of progress in renal cell carcinoma.
|
|
Academic Article
|
Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.
|
|
Academic Article
|
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline.
|
|
Academic Article
|
Randomized controlled trial of expressive writing for patients with renal cell carcinoma.
|
|
Academic Article
|
Port-site metastasis: the influence of biology.
|
|
Academic Article
|
Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes.
|
|
Academic Article
|
Presurgical therapy in metastatic renal cell carcinoma.
|
|
Academic Article
|
Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
|
|
Academic Article
|
Patterns of intervention for renal lesions in von Hippel-Lindau disease.
|
|
Academic Article
|
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
|
|
Academic Article
|
Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors.
|
|
Academic Article
|
Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.
|
|
Academic Article
|
Prognostic models: from the fates to the future.
|
|
Academic Article
|
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
|
|
Academic Article
|
Prognostic and predictive factors in the targeted therapy era: filling in the blanks.
|
|
Academic Article
|
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
|
|
Academic Article
|
Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.
|
|
Academic Article
|
Systemic therapy for sarcomatoid renal cell carcinoma.
|
|
Academic Article
|
Kidney cancer.
|
|
Academic Article
|
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Axitinib in the treatment of metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
|
|
Academic Article
|
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
|
|
Academic Article
|
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
|
|
Academic Article
|
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
|
|
Academic Article
|
Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects.
|
|
Academic Article
|
Kidney cancer, version 2.2014.
|
|
Academic Article
|
Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.
|
|
Academic Article
|
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
|
|
Academic Article
|
NCCN clinical practice guidelines in oncology: kidney cancer.
|
|
Academic Article
|
Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment.
|
|
Academic Article
|
Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study.
|
|
Academic Article
|
Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results.
|
|
Academic Article
|
Molecular markers to predict response to therapy.
|
|
Academic Article
|
Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.
|
|
Academic Article
|
Partial nephrectomy in the setting of metastatic renal cell carcinoma.
|
|
Academic Article
|
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
|
|
Academic Article
|
Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma.
|
|
Academic Article
|
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
|
|
Academic Article
|
Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis.
|
|
Academic Article
|
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.
|
|
Academic Article
|
Genetic kidney cancer syndromes.
|
|
Academic Article
|
Renal cell carcinoma.
|
|
Academic Article
|
First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
|
|
Academic Article
|
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Kidney cancer, version 3.2015.
|
|
Academic Article
|
Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
|
|
Academic Article
|
Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy.
|
|
Academic Article
|
Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.
|
|
Academic Article
|
Kidney cancer: current and novel treatment options.
|
|
Academic Article
|
Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.
|
|
Academic Article
|
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.
|
|
Academic Article
|
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
|
|
Academic Article
|
The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma.
|
|
Academic Article
|
Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.
|
|
Academic Article
|
High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
|
|
Academic Article
|
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
|
|
Academic Article
|
Kidney cancer
|
|
Academic Article
|
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
|
Academic Article
|
HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.
|
|
Academic Article
|
BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.
|
|
Academic Article
|
Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.
|
|
Academic Article
|
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
|
|
Academic Article
|
The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial.
|
|
Academic Article
|
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
|
|
Academic Article
|
Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival.
|
|
Academic Article
|
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
|
|
Academic Article
|
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
|
|
Academic Article
|
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
|
|
Academic Article
|
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
|
|
Academic Article
|
Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy.
|
|
Academic Article
|
The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.
|
|
Academic Article
|
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support.
|
|
Academic Article
|
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.
|
|
Academic Article
|
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
|
|
Academic Article
|
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
|
|
Academic Article
|
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
|
|
Academic Article
|
Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL.
|
|
Academic Article
|
Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
|
|
Academic Article
|
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma.
|
|
Academic Article
|
Recommendations for the Management of Rare Kidney Cancers.
|
|
Academic Article
|
Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
|
|
Academic Article
|
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
|
|
Academic Article
|
Incorporating New Systemic Therapies in Kidney Cancer Treatment.
|
|
Academic Article
|
Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.
|
|
Academic Article
|
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
|
|
Academic Article
|
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Updates to the Management of Kidney Cancer.
|
|
Academic Article
|
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
|
|
Academic Article
|
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
|
|
Academic Article
|
Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.
|
|
Academic Article
|
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
|
|
Academic Article
|
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
|
|
Academic Article
|
Durable complete response in renal cell carcinoma clinical trials.
|
|
Academic Article
|
NCCN Guidelines Updates: Management of Metastatic Kidney Cancer.
|
|
Academic Article
|
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.
|
|
Academic Article
|
MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma.
|
|
Academic Article
|
Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma.
|
|
Academic Article
|
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.
|
|
Academic Article
|
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
|
|
Academic Article
|
Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
|
|
Academic Article
|
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
|
|
Academic Article
|
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.
|
|
Academic Article
|
Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer.
|
|
Academic Article
|
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
|
|
Academic Article
|
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
|
|
Academic Article
|
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
|
|
Academic Article
|
Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease.
|
|
Academic Article
|
Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma.
|
|
Academic Article
|
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.
|
|
Academic Article
|
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials.
|
|
Academic Article
|
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
|
|
Academic Article
|
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
|
|
Academic Article
|
Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients.
|
|
Academic Article
|
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
|
|
Academic Article
|
Inhibition of hypoxia-inducible factor-2a in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
|
|
Academic Article
|
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
|
|
Academic Article
|
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages.
|
|
Academic Article
|
Correction: Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer.
|
|
Academic Article
|
Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
|
|
Academic Article
|
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma.
|
|
Academic Article
|
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement.
|
|
Academic Article
|
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
|
|
Academic Article
|
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
|
|
Academic Article
|
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
|
|
Academic Article
|
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
|
|
Academic Article
|
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.
|
|
Academic Article
|
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
|
|
Academic Article
|
VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions.
|
|
Academic Article
|
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.
|
|
Academic Article
|
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
|
|
Academic Article
|
Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL.
|
|
Academic Article
|
Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.
|
|
Academic Article
|
Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.
|
|
Academic Article
|
Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study.
|
|
Academic Article
|
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
|
|
Academic Article
|
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer.
|
|
Academic Article
|
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
|
|
Academic Article
|
Management of Brain Metastases in Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
|
|
Academic Article
|
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
|
|
Academic Article
|
NCCN Guidelines? Insights: Kidney Cancer, Version 2.2024.
|
|
Academic Article
|
YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial.
|